Sector ratings Definium Therapeutics, Inc.

Equities

Real-time Estimate Cboe BZX Other stock markets 03:54:28 2026-05-19 pm EDT			5-day change	1st Jan Change
20.03 ^USD	-2.20%		-5.01%	+50.11%

May. 12	Definium Therapeutics Begins Patient Dosing in Ascend Phase 3 Depression Trial	MT
May. 12	Definium Therapeutics, Inc. Announces First Patient Dosed In Ascend, The Second Phase 3 Pivotal Study Of DT120 ODT In Major Depressive Disorder	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Financial revisions	Global Valuation	Visibility	Consensus
DEFINIUM THERAPEUTICS, INC.	2.23B	-	A	-		-
LONZA GROUP AG	41.61B		AAA
BEONE MEDICINES AG	32.58B		-
REVOLUTION MEDICINES, INC.	30.69B	-	B	-		-
IQVIA HOLDINGS INC.	28.84B		AAA
CELLTRION, INC.	25.65B		A
ASCENDIS PHARMA A/S	14.76B	-	-	-		-		-
REGENCELL BIOSCIENCE HOLDINGS LIMITED	13.74B	-	-	-	-	-	-	-
IONIS PHARMACEUTICALS, INC.	11.98B	-	A	-		-
EUROFINS SCIENTIFIC SE	12.3B		AA
MEDPACE HOLDINGS, INC.	12.01B		BBB
PRAXIS PRECISION MEDICINES, INC.	8.94B	-	B	-		-
ABIVAX	8.87B	-	BBB	-		-
ICON PUBLIC LIMITED COMPANY	8.69B		AAA
TEMPUS AI, INC.	7.83B		A			-
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	7.22B		AA
BACHEM HOLDING AG	7.28B		A
QIAGEN N.V.	6.99B		AAA
BIO-TECHNE CORPORATION	6.96B		AA
KYMERA THERAPEUTICS, INC.	6.55B	-	BBB	-		-
Average	14.79B		AA
Weighted average by Cap.			AA